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Introduction: Several independent groups have recently reported novel molecular
subtypes in colorectal cancer (CRC). A systematic comparison of the reported subtypes
is needed to determine common findings and facilitate translation into the clinic. A
collaborative effort by the CRCSC was initiated to enable open data sharing and
meta-analysis with the goal of establishing a consensus subtyping model.
Methods: CRCSC participants, representing more than 15 institutions, analyzed 30+
gene expression sets, including multiple platforms and sample preparation methods.
Six previously published classifiers (with 3-6 subtypes each) were applied to a dataset
comprising more than 5,000 samples, consisting primarily of stage II-III colon cancer.
A central independent team (Sage Bionetworks) provided analysis concordance of
subtype calls, and clinical/molecular/pathology annotation with methodology derived
through consensus.
Results: Despite variation in the datasets and classification methodology in the separate
published subtypes, there were 4 consensus molecular subtypes (CMS1-4) clearly defined
by the concordance analysis, as indicated by a high degree of interconnectivity among the
subtype calls from the 6 methods. CMS1 (∼15%) was enriched for MSI, right-side tumors,
older age, females, hypermutation, BRAFmut and immune pathway activation. Both
CMS2 and 3 displayed epithelial markers, canonical WNT andMYC pathway activation.
Highly proliferative CMS2 tumors (∼40%) were CIN, MSS, left-sided, TP53 mut with
EGFR upregulation and had better survival rates. CMS3 tumors (∼10%) had low CIN
status, higher proportion of KRAS/PIK3CAmutations and IGFBP2 overexpression. CMS4
tumors (∼20%) were characterized by mesenchymal/TGF-beta signaling upregulation,
younger age at diagnosis, NOTCH3/VEGFR2 overexpression and worse survival outcomes.
The remaining samples (∼15%) did not have a consensus assignment, which may be
attributed to additional minor subtypes. Further refinement is anticipated.
Conclusion: This consortium represents the first effort to generate consensus cancer
subtypes and a major step forward for precision medicine in CRC. By comparing
multiple classifiers we were able to identify four biologically distinct subtypes of CRC
with unique clinical and molecular markers, a remarkable overlap considering different
methodologies and datasets used by individual groups. Our efforts on improving this
consensus classification system and correlating subtypes with benefit from adjuvant
chemotherapies/response to targeted agents will be presented.
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